471938-27-9

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 2971-79-1 isonipecotic acid methyl ester 
• 7595-60-0 methyl 1-(4-nitrophenyl)piperidine-4-carboxylate 

Downstream Products

• 1085839-59-3 1-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-piperidine-4-carboxylic acid methyl ester 
• 1085839-92-4 1-(1-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-piperidine-4-carbonyl)-piperidine-4-carboxylic acid ethyl ester 
• 1085839-61-7 1-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-piperidine-4-carboxylic acid 
• 471937-86-7 [1-(4-aminophenyl)piperidin-4-yl]methanol 

Relevant academic research and scientific papers

Porphyrin Donor and Tunable Push–Pull Acceptor Conjugates—Experimental Investigation of Marcus Theory

We report on a series of electron donor–acceptor conjugates incorporating a ZnII–porphyrin-based electron donor and a variety of non-conjugated rigid linkers connecting to push–pull chromophores as electron acceptors. The electron acceptors comprize multicyanobutadienes or extended tetracyanoquinodimethane analogues with first reduction potentials ranging from ?1.67 to ?0.23 V vs. Fc+/Fc in CH2Cl2, which are accessible through a final-step cycloaddition–retroelectrocyclization (CA-RE) reaction. Characterization of the conjugates includes electrochemistry, spectroelectrochemistry, DFT calculations, and photophysical measurements in a range of solvents. The collected data allows for the construction of multiple Marcus curves that consider electron-acceptor strength, linker length, and solvent, with data points extending well into the inverted region. The enhancement of electron–vibration couplings, resulting from the rigid spacers and, in particular, multicyano-groups in the conformationally highly fixed push–pull acceptor chromophores affects the charge-recombination kinetics in the inverted region drastically.

HETEROCYCLIC COMPOUND

The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS

Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

Thiohydantoins and use thereof for treating diabetes

The invention relates to 2-thiohydantoin derivative compounds selected from compounds of general formula (I): as defined in the claims, and to their addition salts with an acid, notably pharmaceutically acceptable salts. The invention also relates to thei